on Biophytis (EPA:ALBPS)
Biophytis Initiates Phase 2 OBA Clinical Trial for Obesity Treatment
Biophytis SA, a biotechnology firm specializing in treatments for age-related diseases, has confirmed the launch of its Phase 2 OBA clinical trial targeting obesity. The study aims to evaluate the efficacy and safety of their drug candidate, BIO101, in countering muscle strength loss induced by GLP-1 agonists in obese patients. The trial is scheduled to commence in early 2025.
Following a capital increase of €2.6 million and promising preclinical outcomes, Biophytis is poised to advance its clinical studies. The U.S. FDA's Investigational New Drug clearance in July 2024 marked a significant step for the OBA program. The initiative leverages the expertise of Professor Marc-André Cornier in the obesity domain.
The company is actively seeking a pharmaceutical partner to facilitate the subsequent clinical development and market launch in North America.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news